HMGB1 bound to cisplatin-DNA adducts undergoes extensive acetylation and phosphorylation in vivo.
Ontology highlight
ABSTRACT: Cisplatin, one of the most effective anticancer drugs, is a DNA-damaging agent that induces cell death primarily by apoptosis. For many years, HMGB1 has been known to be a recognition protein for cisplatin-DNA lesions. Here, an application of a biomolecular probe based on a peptide-oligonucleotide conjugate is presented as a novel method for investigating this recognition process in vivo. Proteins known to be involved in the recognition of cisplatin-damaged DNA were pulled down and identified, including members of the HMGB family and a number of other proteins. Interestingly, at least 4 subforms of HMGB1 bind to cisplatin-DNA adducts. These proteins were further identified as post-translationally acetylated or phosphorylated forms of HMGB1. These results provide a rich pool of protein cand
SUBMITTER: He Y
PROVIDER: S-EPMC5810237 | biostudies-literature | 2015 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA